Author's response to reviews

Title: Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases

Authors:

Yanzhi Zhang (yearch_hmu@126.com)
Jiali Dai (daijiali999@163.com)
Keely M. McNamara (kmcnamara@patholo2.med.tohoku.ac.jp)
Bing Bai (baib_hmu@126.com)
Mumu Shi (shimumu2009@139.com)
Monica S.M. Chan (drmonicachan@hotmail.com)
Ming Liu (liuming_hmu@126.com)
Hironobu Sasano (hsasano@patholo2.med.tohoku.ac.jp)
Xiuli Wang (wangxiulinihao@sina.cn)
Xiaolei Li (xiaoleili2004@163.com)
Lijuan Liu (lij19971997@163.com)
Ying Ma (haorenmaying@126.com)
Shuwen Cao (caosw_dqytzdy@126.com)
Yanchun Xing (xingyc_lnhospital@126.com)
Baoshan Zhao (zhaobs_hmu@126.com)
Yinli Song (songyl_hmu@126.com)
Lin Wang (wangl_cmu@126.com)

Version: 5
Date: 24 June 2015

Author's response to reviews:

MS: 7633034831623497
Prognostic significance of proline, glutamic acid, leucine rich protein 1 in triple-negative breast cancer: a retrospective study on 129 cases

# Comments from editor

Your manuscript has now been peer reviewed and assessed by our senior editor. See editorial request below.

**copyediting: We recommend that you copyedit the paper to improve the style of written English. If this is not possible, you may need to use a professional language editing service. For authors who wish to have the language in their manuscript edited by a native-English speaker with scientific expertise, BioMed Central recommends Edanz (www.edanzediting.com/bmc1). BioMed Central has negotiated a 10% discount to the fee charged to BioMed Central authors by Edanz. Use of an editing service is neither a requirement nor a guarantee of acceptance for publication. For more information, see our FAQ on language editing services at http://www.biomedcentral.com/authors/authorfaq/editing.
Response#
Further copyediting had been made by Edanz. If necessary, a certification of copyediting work can be provided by Edanz.